RIFARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 185,029 | 132,973 | 113,294 | 131,588 | 63,764 | 66,493 | 60,776 | 32,600 |
| Profit before tax | -46,103 | -13,286 | -3,918 | 778 | -21,051 | -8,322 | 476 | -9,267 |
| Net profit | -46,103 | -13,286 | -3,918 | 607 | -21,051 | -8,322 | 439 | -9,267 |
| Equity | 65,393 | 52,107 | 48,189 | 48,796 | 27,745 | 19,423 | 19,862 | 10,595 |
| Liabilities | 83,192 | 47,916 | 53,290 | 65,659 | 41,891 | 45,419 | 36,962 | 27,168 |
| Non-current assets | 40,207 | 24,785 | 16,444 | 11,735 | 5,478 | 1,331 | 1,187 | 545 |
| Current assets | 108,108 | 75,027 | 84,829 | 102,567 | 64,158 | 63,320 | 55,448 | 37,020 |
| Total assets | 148,315 | 99,812 | 101,273 | 114,302 | 69,636 | 64,651 | 56,635 | 37,565 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 16,978 | 16,265 | 11,141 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -39.8% | -28.1% | -14.8% | +16.1% | -51.5% | +4.3% | -8.6% | -46.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -31.1% | -13.3% | -3.9% | 0.5% | -30.2% | -12.9% | 0.8% | -24.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -70.5% | -25.5% | -8.1% | 1.2% | -75.9% | -42.8% | 2.2% | -87.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -24.9% | -10.0% | -3.5% | 0.5% | -33.0% | -12.5% | 0.7% | -28.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -24.9% | -10.0% | -3.5% | 0.6% | -33.0% | -12.5% | 0.8% | -28.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.3 | 0.9 | 1.1 | 1.3 | 1.5 | 2.3 | 1.9 | 2.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 46,257 | 44,324 | 37,765 | 43,863 | 21,255 | 24,179 | 30,388 | 16,300 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
RIFARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-01 | 2026-01-12 | 0.19 |
| 2025-12-16 | 2025-12-30 | 0.19 |
| 2025-01-16 | 2025-01-19 | 92.07 |
| 2023-10-25 | 2023-11-13 | 0.12 |
| 2023-08-17 | 2023-08-21 | 258.10 |
| 2022-10-18 | 2022-11-13 | 0.18 |
| 2022-09-16 | 2022-10-12 | 0.18 |
| 2022-08-23 | 2022-09-12 | 0.18 |
| 2022-07-18 | 2022-08-11 | 0.19 |
| 2022-06-16 | 2022-07-10 | 0.19 |
RIFARMA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
RIFARMA, UAB (code 123951253) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025 the company generated revenue of €32.6K, which was 46.4% lower year on year and 51.0% below the 2023 level. Net profit turned into a loss of €9.3K, after a small profit of €439 in 2024 and a loss of €8.3K in 2023, indicating a clear weakening in earnings after one positive year. The 2025 profit margin was -28.4%. The balance sheet also contracted: total assets fell to €37.6K from €56.6K in 2024 and €64.7K in 2023. Equity decreased to €10.6K, while liabilities were €27.2K, resulting in an equity ratio of 28.2% and debt-to-equity of 2.56. Asset turnover stood at 0.87x. Revenue per employee was €16.3K, and profit per employee was -€4.6K. Overall, the 2025 figures show a smaller business scale and weaker profitability than in the previous two years.